EUVIMEDEUVIMED entdecken
Crossref

Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors

Prospektive Bewertung der Reaktivierung des Hepatitis-B-Virus bei Krebspatient:innen unter Tyrosinkinaseinhibitoren

Hung-Chih Chiu iD, Chien-Chung Lin iD, Chun-Hui Lee iD, Yi-Ting Yen iD, Yau-Lin Tseng iD, Chin-Wei Kuo iD, Chian-Wei Chen, Jeng-Shiuan Tsai iD, Ya-Ting Hsu iD, Shih-Chieh Chien iD, Yen-Cheng Chiu, Ming-Hsuan Wu und 2 weitere

Journal of Medical Virology · 2026-11 · 98 (11)

DOI: 10.1002/jmv.71206 ↗

Auf einen Blick

Bei 79 Patient:innen unter Tyrosinkinaseinhibitoren trat eine HBV-Reaktivierung auf, vor allem bei HBsAg-positiven Personen. Bei Patient:innen mit resolved HBV war sie seltener, aber vorhanden.

Fragestellung

Wie häufig tritt eine HBV-Reaktivierung unter Tyrosinkinaseinhibitoren bei Krebspatient:innen mit chronischer oder durchgemachter HBV-Infektion auf?

Methode

Prospektive Studie an einem taiwanesischen Zentrum; Monitoring von HBV-DNA und Leberenzymen 12-wöchentlich sowie HBsAg 24-wöchentlich; Definition nach AASLD, sekundär APASL und EASL.

Ergebnisse

Unter 79 Patient:innen kam es bei 7 zu HBVr (8,9 %; 95 %-KI 4,4 %–17,2 %). Bei HBsAg-positiven Patient:innen waren es 5/20 (25,0 %; 95 %-KI 11,2 %–46,9 %), bei resolved HBV 2/59 (3,4 %; 95 %-KI 0,9 %–11,5 %).

Einschränkungen

Transiente Schübe zwischen den Untersuchungen konnten nicht ausgeschlossen werden.

Schlussfolgerung der Autor:innen

HBVr war bei HBsAg-positiven Patient:innen häufig und bei resolved HBV seltener, aber nicht vernachlässigbar, unter TKIs.

Kernaussagen

  • HBVr insgesamt bei 7 von 79 Patient:innen
  • 25,0 % bei HBsAg-positiven vs. 3,4 % bei resolved HBV
  • Keine HBVr-assoziierte Hepatitis-Exazerbation nach Studiendefinition

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 02.11.2026. Verfasst von Hung-Chih Chiu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology and Hepatology, National Cheng Kung University Hospital, College of Medicine, National …. Hauptthemen laut MEDLINE: Virus Activation, Hepatitis B virus, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Cheng Kung University, Tainan, Taiwan.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on hepatitis B virus reactivation (HBVr) during tyrosine kinase inhibitor (TKI) therapy remain limited. We prospectively enrolled patients with chronic or resolved HBV receiving TKIs for lung cancer or chronic myeloid leukemia at one Taiwanese center (January 2023–March 2025). HBV DNA and liver enzymes were monitored 12‐weekly and HBsAg 24‐weekly. HBVr was defined by AASLD criteria, with APASL and EASL definitions applied secondarily. Among 79 patients (20 HBsAg‐positive, 59 resolved HBV), none received antiviral prophylaxis. Median follow‐up was 42 weeks (IQR, 19–65). HBVr occurred in 7 (8.9%; 95% CI, 4.4%–17.2%): 5 HBsAg‐positive (25.0%; 95% CI, 11.2%–46.9%), and 2 with resolved HBV (3.4%; 95% CI, 0.9%–11.5%). APASL and EASL definitions yielded 30.0% and 35.0% in HBsAg‐positive patients, with no additional events in resolved HBV. No HBVr‐associated hepatitis flare meeting the study definition was observed, although transient flares between assessments could not be excluded and deterioration in one fatal case was attributed clinically to sepsis. Median HBVr detection time was 19 weeks (IQR, 14–30). Week‐48 Kaplan–Meier HBVr incidence was 37.5% (95% CI, 17.0%–69.5%) in HBsAg‐positive and 5.6% (95% CI, 1.4%–21.2%) in resolved HBV (log‐rank p < 0.001); Aalen–Johansen estimates were 28.3% (95% CI, 9.5%–50.9%) and 4.3% (95% CI, 0.8%–13.2%), respectively. In exploratory Firth‐corrected regression, HBsAg positivity was associated with HBVr (HR, 6.95; 95% CI, 1.60–40.19), while osimertinib exposure was not. HBVr was common among HBsAg‐positive patients and less common but not negligible among those with resolved HBV receiving TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus ActivationHepatitis B virusProtein Kinase InhibitorsLung NeoplasmsHepatitis B, ChronicHumansFemaleMaleMiddle AgedProspective StudiesAgedDNA, ViralHepatitis B Surface AntigensTaiwanTyrosine Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdultAntiviral Agents

Stichwörter der Autor:innen

antiviral prophylaxischronic myeloid leukemiahepatitis B virus reactivationlung cancertyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsDNA, ViralHepatitis B Surface AntigensTyrosine Kinase InhibitorsAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Internal Medicine, Division of Chest Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Surgery, Division of Thoracic Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Internal Medicine, Division of Hematology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Hung-Chih Chiu, Chien-Chung Lin, Chun-Hui Lee, Yi-Ting Yen, Yau-Lin Tseng, Chin-Wei Kuo, Jeng-Shiuan Tsai, Ya-Ting Hsu, Shih-Chieh Chien, Meng-Hsuan Lu, Pin-Nan Cheng

Förderung

  • National Cheng Kung University, Tainan, Taiwan

Zitieren

APA

Chiu, H. C., Lin, C. C., Lee, C. H., Yen, Y. T., Tseng, Y. L., Kuo, C. W., Chen, C. W., Tsai, J. S., Hsu, Y. T., Chien, S. C., Chiu, Y. C., Wu, M. H., Lu, M. H., & Cheng, P. N. (2026). Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors. Journal of Medical Virology, 98(11). https://doi.org/10.1002/jmv.71206

Vancouver

Chiu HC, Lin CC, Lee CH, Yen YT, Tseng YL, Kuo CW, et al. Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors. Journal of Medical Virology. 2026;98(11). doi:10.1002/jmv.71206

BibTeX
@article{Chiu2026,
  author = {Chiu, Hung-Chih and Lin, Chien-Chung and Lee, Chun-Hui and Yen, Yi-Ting and Tseng, Yau-Lin and Kuo, Chin-Wei and Chen, Chian-Wei and Tsai, Jeng-Shiuan and Hsu, Ya-Ting and Chien, Shih-Chieh and Chiu, Yen-Cheng and Wu, Ming-Hsuan and Lu, Meng-Hsuan and Cheng, Pin-Nan},
  title = {Prospective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {11},
  doi = {10.1002/jmv.71206}
}
Kostenlos starten →